Tracking a patient's circulating tumor DNA (ctDNA) can offer insight into how well-targeted therapies work in the early stages of treatment for HER2-positive cancers.
SAN DIEGO — Monitoring a patient's circulating tumor DNA can provide valuable insights on early response to targeted therapies among patients with
Limitations of standard radiographic tumor assessments present challenges in determining clinical response, particularly for patients receiving targeted therapies. Commenting on the potential use of this method in other cancer types with HER2 alterations, Pashtoon Murtaza Kasi, MD, MS, noted that since the study relied on a tumor-informed assay, it would be applicable across diverse tumor types.
During an interview, Dr. Kurzrock explained that FoundationOne Tracker is a personalized ctDNA monitoring assay that allows for the detection of ctDNA in plasma, enabling ongoing liquid-based monitoring and highly sensitive quantification of ctDNA levels as mean tumor molecules per milliliter of plasma.
The researchers also observed that increases in on-treatment ctDNA levels often preceded radiographic evidence of disease progression by a median of 1.3 months. These findings highlight the potential for ctDNA monitoring to complement standard clinical assessments, allowing us to detect treatment response and disease progression earlier than what is possible with imaging alone, Dr. Kurzrock explained during her talk.
"In some centers like ours, ctDNA monitoring is already part of our standard of care since not only does it help from a physician standpoint to have a more accurate and early assessment of response, but patients also appreciate the information gained from ctDNA dynamics," Dr. Kasi said in an interview. He explained that when radiographic findings are equivocal, ctDNA monitoring is an additional tool in their toolbox to help guide care.
Biologics Tumor Genomics Genomic Medicine Targeted Therapy Targeted Cancer Therapy Colorectal Cancer Colorectal Cancer (CRC) Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Liquid Biopsy Fluid Biopsy Fluid Phase Biopsy Cancer Blood Test Cancer Saliva Test Blood Biopsy Serum Biopsy Antineoplastic Drug Anti-Cancer Agents Erlotinib Gefitinib Imatinib
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Expands Approval of Fam-Trastuzumab-Deruxtecan-Nxki for HER2-Positive Gastric CancerThe US Food and Drug Administration (FDA) has expanded the approval of fam-trastuzumab–deruxtecan-nxki (Enhertu; AstraZeneca and Daiichi Sankyo, Inc) to adults with unresectable or metastatic as well as adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who had received a prior trastuzumab-based regimen. This approval provides a new treatment option for patients with limited options.
Read more »
New Transparent AI Predicts Breast Cancer 5 Years OutThe model's easier-to-understand process marks an important milestone in the quest to bring AI to bedside in a meaningful way.
Read more »
Worldwide Prostate Cancer Cases Will Double By 2040, New Study Predicts—Here’s WhyI am a Colorado based reporter covering breaking news with a special emphasis on the entertainment industry, pop culture and sports. I previously covered local news in the greater Boston area, and I graduated from Northeastern University in 2017.
Read more »
6 Ways To Lower Your Risk Of Colon CancerYou may think of cancer as an age-related disease, but it very much affects young people—especially colon cancer. This cancer is now the leading cause of cancer-related deaths for men under 50 and is the second leading cause for women under 50 (behind breast cancer). And its prevalence is only rising. Estimates show that by 2030, colon cancer diagnoses are expected to increase by 90-124% for those 20-34 years of age and by 28-46% for those 35 to 49 years of age. One reason for this is that there is a big lifestyle and environmental component to the disease. In fact, data suggests that around 50% of colon cancer cases can be prevented through lifestyle modifications. And as cancer can take decades to progress, it’s never too early to start to think about prevention. Here’s what you need to know about colon cancer and six habits that could help lower your risk for it.
Read more »
March is Colon Cancer Awareness Month | Second leading cause of cancer deaths in the U.S.March is colon cancer awareness month. According to the American Cancer Society, *excluding skin cancers*, colorectal cancer is the *third* most common cancer.
Read more »
Kate Middleton cancer diagnosis: Princess of Wales undergoing cancer treatmentCatherine, Princess of Wales, has been out of the public eye while she handles a cancer diagnosis,
Read more »